30秒注册登陆，可查看更多信息，结交更多好友，享用更多功能，轻松玩转论坛，白白手拉手欢迎您的加入！
您需要 登录 才可以下载或查看，没有账号？注册新成员
x
下面是这个美国教授今天上午对白白研究回复我的邮件，大家可以一起看看还有一个关于白白的会议纪要，我单独发帖出来给大家，也是这个教授给我的
Dear vitiligo research enthusiast, In the 2 years since our publication appeared in Science Translational Medicine about a new HSP70-based strategy with potential for the treatment of vitiligo, we have been fortunate to obtain some support for follow up studies that will last until the fall. Based on new insights in the disease process, we have also reported on other treatment opportunities over the past 2 years. In fact, investigative Dermatologists have been trying different treatments that may be suitable for vitiligo, with varying results. Groups of investigators are getting together to define ‘improvement’ and how to measure it, to understand the burden of disease, and see what we can learn from genes that seem to be involved, to start biobanks and develop models that accurately reflect disease so we can test treatments. There is a lot of movement in the field and it is always important to hear from you! In fact, we hope to get together with patients, physicians and researchers to discuss the latest advances (and setbacks) in vitiligo research and treatment with you at a meeting in Orange, CA that will take place onSunday, September 27, 2015 in the Doubletree hotel. If you can make it there the evening before, there will be a vitiligo social at Dave and Busters, close to the conference hotel. I’m attaching an information sheet to tell you all about it and let you know how you can sign up. I hope to see you there, Caroline Le Poole Ph.D. please find my more extensive reply below Dear vitiligo research enthusiast, Thank you for your email. I can only imagine how difficult it must be to wait for the next development in vitiligo research. However, several groups including our own have again reported findings pointing to possible treatment methods for vitiligo that have yet to be brought to the clinic. These are positive developments showing that we, as researchers, continue to work hard to understand what vitiligo is, and to come up with a possible treatment. Before any new finding is brought to a clinical trial though, a few years will pass during which time further elaborate testing is needed to show that a treatment is safe and it works in other settings, and the investigators need to seek approval for using the drug in patients. The drug has to be prepared and labeled. Only then can the testing begin on a very, very small scale, assuming we continue to find support to cover the expenses in these times when research dollars are hard to come by. Kindly understand that I cannot provide updates to you individually, as it takes time away from the research itself. Rather, if you want to see whether there are new developments, some suggesti** will be to search vitiligo patient society websites. From time to time, you can also search clinicaltrials.gov to see if there are any active clinical trials open that address vitiligo. We are excited about our research to understand the causes and ultimately develop curative measures for your skin disorder. Since I’ve started working on vitiligo more than 20 years ago (my thesis in 1993 was about vitiligo as well) we have gained a lot in understanding why some people develop vitiligo. In this period of time, we’ve been able to identify vitiligo as an autoimmune disease. This means that your immune system mis-identifies your own pigment cells as ‘foreign’ and starts attacking them. We have figured out that it is primarily a specific immune cell, the T cell, that is resp**ible for killing pigment cells, leaving the skin without a source of pigment. We know a lot about what it is that the T cell sees to identify its targets. There have been major attempts to identify hereditary factors in vitiligo, and the genes identified to date support our findings to show that vitiligo is an autoimmune disease. We then wanted to understand why patients develop depigmentation when they do. How does ‘stress’ ultimately translate into an autoimmune resp**e targeting melanocytes? We figured that if this resp**e is funneled through a single molecule, we can possibly block its activity and halt disease development. This is what we set out to do when we initially investigated the role of HSP70 in vitiligo. We then engineered a variant to the molecule that works like an ‘off-switch’ in our mouse models of spontaneous vitiligo. We characterized what happened to immune resp**es in treated animals, and then found that the same changes in immune activation can also be found in (treated) human skin samples. Our 2013 publication in Science Translational Medicine is the culmination of many years of work, and we hope to continue our research so we will be able to bring our findings to the clinic. If everything were decided in our favor, the earliest we could start a clinical trial to determine the safety of our drug in human patients will be 2 years. In the meantime, we will acquire regulatory approvals, identify sources of support to perform the trials, and test the safety and efficacy of our product in different models. We have already applied for further funding to support this work and our Institution, Loyola, has applied for a patent to cover the technology. In fact, we have since acquired some additional funding that supports additional studies for the current academic year. However, it will definitely be a few years before we can start a clinical trial even if all our preliminary studies are successful. That’s just how the process works, and it has to be safe. We certainly plan to further pursue this and other avenues to treat vitiligo. In the meantime, I would like to thank you wholeheartedly for your supportive comments, and some of you for the important samples you have already provided for our research to date. I hope we can count on you to help us out when we need to test our drug, look at or ask for samples of your skin, test your blood samples or fill questionnaires in the future. I am sorry that I cannot respond to each of you individually, but I will store your resp**es to address you in the future, unless you tell me otherwise. If you have images of your vitiligo that you are willing to share with me, I would love use such images to put together one or more slides for presentati** about our research. Don’t send me anything you are not comfortable with if I share the image(s) with colleagues or include it in publicati**, and let me know if there are parts of the image you would like us to cut to make sure you cannot be identified. And please do not feel obligated to send me an image if you do not want to. I sincerely thank you for your time to address us about our research and hope that our paths will cross again. Caroline Le Poole I. Caroline Le Poole Ph.D. Professor of Pathology, Microbiology and Immunology Tumor Immunology and Immunotherapy Research Program Loyola University Chicago Cardinal Bernardin Cancer Center Rm 203 2160 South 1st Avenue Maywood, IL 60153 USA Tel 1-708-327-2032 (office) / 1-708-327-3138 (lab)
| 
[复制链接]
发表于 2015-4-16 13:34:42
楼主
发表于 2015-4-16 14:10:10
